Wall Street brokers expect Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) to post earnings per share of $0.28 for the current quarter, reports Zacks Investment Research. Five analysts have made earnings estimates for Elanco Animal Health, with the lowest EPS estimate being $0.25 and the highest estimate $0.36. Elanco Animal Health also posted earnings per share of $0.28 in the same quarter last year. The company is due to release its next quarterly earnings report on Monday, January 1.
According to Zacks, analysts expect Elanco Animal Health to report annual earnings of $1.17 per share for the current fiscal year, with EPS estimates ranging from $1.15 to $1.21. For next year, analysts expect the company to report earnings of $1.48 per share, with EPS estimates ranging from $1.44 to $1.60. Zacks EPS calculations are an average based on a survey of research companies that provide coverage for Elanco Animal Health.
Elanco Animal Health (NYSE:ELAN – Get Rating) last released its quarterly results on Monday, May 9. The company reported EPS of $0.36 for the quarter, beating analysts’ consensus estimate of $0.35 by $0.01. The company posted revenue of $1.23 billion for the quarter, compared to analysts’ estimates of $1.22 billion. Elanco Animal Health recorded a negative net margin of 7.65% and a positive return on equity of 6.61%. Elanco Animal Health revenue decreased 1.4% compared to the same quarter last year. In the same quarter a year earlier, the company earned $0.37 per share.
ELAN has been the subject of a number of recent research reports. Barclays raised its price target on shares of Elanco Animal Health from $30.00 to $32.00 and gave the stock an “equal weight” rating in a Monday, February 28 report. Zacks Investment Research downgraded shares of Elanco Animal Health from a “hold” rating to a “sell” rating in a Tuesday, May 10, report. Goldman Sachs Group lowered its price target on shares of Elanco Animal Health from $37.00 to $32.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Morgan Stanley lowered its price target on shares of Elanco Animal Health to $37.00 and set an “overweight” rating on the stock in a Tuesday, May 17 report. One analyst has assigned the stock a sell rating, three have issued a hold rating and three have assigned the company’s stock a buy rating. According to MarketBeat.com, Elanco Animal Health currently has an average rating of “Hold” and a consensus target price of $34.60.
Separately, director John P. Bilbrey acquired 10,000 shares of the company in a transaction dated Wednesday, May 11. The shares were purchased at an average price of $22.03 per share, for a total transaction of $220,300.00. Following the completion of the acquisition, the director now owns 34,222 shares of the company, valued at $753,910.66. The acquisition was disclosed in a filing with the SEC, which is available on the SEC’s website. Additionally, director R David Hoover acquired 5,000 shares of the company in a transaction dated Tuesday, March 1. The shares were purchased at an average price of $28.66 per share, for a total transaction of $143,300.00. Disclosure of this purchase can be found here. 6.40% of the shares are held by insiders.
A number of hedge funds and other institutional investors have recently changed their positions in the stock. Herold Advisors Inc. bought a new stake in Elanco Animal Health in Q1 for $26,000. Tcwp LLC bought a new position in shares of Elanco Animal Health during the first quarter, valued at around $29,000. CKW Financial Group bought a new position in Elanco Animal Health during the fourth quarter worth approximately $30,000. Clearstead Advisors LLC purchased a new stake in Elanco Animal Health in Q3 worth approximately $31,000. Finally, IndexIQ Advisors LLC acquired a new stake in Elanco Animal Health in Q1 worth approximately $32,000.
NYSE:ELAN shares opened at $24.27 on Friday. The company has a market capitalization of $11.51 billion, a PE ratio of -32.80, a growth price-earnings ratio of 1.13 and a beta of 0.74. The company’s fifty-day moving average is $25.45 and its 200-day moving average is $27.24. The company has a debt ratio of 0.80, a quick ratio of 1.41 and a current ratio of 2.44. Elanco Animal Health has a 52-week minimum of $20.51 and a 52-week maximum of $37.49.
Company Profile Elanco Animal Health (Get an assessment)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets pet and farm animal products. It offers disease prevention products for companion animals, such as parasiticide products and vaccines that protect animals against worms, fleas and ticks under the brand names Seresto, Advantage, Advantix and Advocate; companion animal health therapies for pain, osteoarthritis, ear infections, cardiovascular and dermatological indications in dogs and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides and other products for poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Get a Free Copy of Zacks’ Research Report on Elanco Animal Health (ELAN)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily newsletter.